Find out what Mozobil could do for you

Mozobil is approved by the FDA to be used in combination with another
agent filgrastim to mobilize hematopoietic stem cells to the peripheral blood
for collection and subsequent autologous transplantation in patients living with
non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).

Learn how Mozobil could help

Supporting you through stem cell mobilization

Our passion is to facilitate access and provide support to patients. Explore available resources, including the Sanofi Patient Connection Support Program.

Learn More